Gender affirming medical care of transgender youth

被引:48
作者
Salas-Humara, Caroline [1 ]
Sequeira, Gina M. [2 ]
Rossi, Wilma [3 ]
Dhar, Cherie Priya [4 ]
机构
[1] NYU, Dept Pediat, Sch Med, Div Adolescent Med, New York, NY 10016 USA
[2] UPMC Childrens Hosp Pittsburgh, Ctr Adolescent & Young Adult Hlth, Pittsburgh, PA USA
[3] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[4] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Evanston, IL 60208 USA
关键词
SEX HORMONE-THERAPY; BONE-MINERAL DENSITY; TESTOSTERONE REPLACEMENT THERAPY; CENTRAL PRECOCIOUS PUBERTY; CYPROTERONE-ACETATE; AGONIST TREATMENT; ANALOG TREATMENT; BREAST-CANCER; VENOUS THROMBOEMBOLISM; TRANSSEXUAL PATIENTS;
D O I
10.1016/j.cppeds.2019.100683
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The number of gender diverse and transgender youth presenting for treatment are increasing. This is a vulnerable population with unique medical needs; it is essential that all pediatricians attain an adequate level of knowledge and comfort caring for these youth so that their health outcomes may be improved. There are several organizations which provide clinical practice guidelines for the treatment of transgender youth including the WPATH and the Endocrine Society and they recommend that certain eligibility criteria should be met prior to initiation of gender affirming hormones. Medical intervention for transgender youth can be broken down into stages based on pubertal development: pre-pubertal, pubertal and post-pubertal. Pre-pubertally no medical intervention is recommended. Once puberty has commenced, youth are eligible for puberty blockers; and post-pubertally, youth are eligible for feminizing and masculinizing hormone regimens. Treatment with gonadotropin releasing hormone agonists are used to block puberty. Their function is many-fold: to pause puberty so that the youth may explore their gender identity, to delay the development of (irreversible) secondary sex characteristics, and to obviate the need for future gender affirmation surgeries. Masculinizing hormone regimens consists of testosterone and feminizing hormone regimens consist of both estradiol as well as spironolactone. In short term studies gender affirming hormone treatment with both estradiol and testosterone has been found to be safe and improve mental health and quality of life outcomes; additional long term studies are needed to further elucidate the implications of gender affirming hormones on physical and mental health in transgender patients. There are a variety of surgeries that transgender individuals may desire in order to affirm their gender identity; it is important for providers to understand that desire for medical interventions is variable among persons and that a discussion about individual desires for surgical options is recommended.
引用
收藏
页数:21
相关论文
共 89 条
[1]  
Ahmad Shazia, 2017, Transgend Health, V2, P176, DOI 10.1089/trgh.2017.0023
[2]   Female-to-Male Gender-Affirming Chest Reconstruction Surgery [J].
Ammari, Tareq ;
Sluiter, Emily C. ;
Gast, Katherine ;
Kuzon Jr, William M. .
AESTHETIC SURGERY JOURNAL, 2019, 39 (02) :150-163
[3]   Incidence of Venous Thromboembolism in Transgender Women Receiving Oral Estradiol [J].
Arnold, Justin D. ;
Sarkodie, Eleanor P. ;
Coleman, Megan E. ;
Goldstein, Deborah A. .
Journal of Sexual Medicine, 2016, 13 (11) :1773-1777
[4]   Testosterone Induces Erythrocytosis via Increased Erythropoietin and Suppressed Hepcidin: Evidence for a New Erythropoietin/Hemoglobin Set Point [J].
Bachman, Eric ;
Travison, Thomas G. ;
Basaria, Shehzad ;
Davda, Maithili N. ;
Guo, Wen ;
Li, Michelle ;
Westfall, John Connor ;
Bae, Harold ;
Gordeuk, Victor ;
Bhasin, Shalender .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2014, 69 (06) :725-735
[5]   Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues [J].
Bertelloni, S ;
Baroncelli, GI ;
Ferdeghini, M ;
Menchini-Fabris, F ;
Saggese, G .
EUROPEAN JOURNAL OF PEDIATRICS, 2000, 159 (05) :369-374
[6]   Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline [J].
Bhasin, Shalender ;
Brito, Juan P. ;
Cunningham, Glenn R. ;
Hayes, Frances J. ;
Hodis, Howard N. ;
Matsumoto, Alvin M. ;
Snyder, Peter J. ;
Swerdloff, Ronald S. ;
Wu, Frederick C. ;
Yialamas, Maria A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (05) :1715-1744
[7]   Diagnosis and treatment of hypogonadism in men [J].
Bhasin, Shalender ;
Basaria, Shehzad .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 25 (02) :251-270
[8]   Incidence of breast cancer in a cohort of 5,135 transgender veterans [J].
Brown, George R. ;
Jones, Kenneth T. .
BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) :191-198
[9]   Transgender adolescents and acne: A cases series [J].
Campos-Munoz, Lucia ;
Lopez-De Lara, Diego ;
Rodriguez-Rojo, Marina L. ;
Conde-Taboada, Alberto ;
Lopez-Bran, Eduardo .
PEDIATRIC DERMATOLOGY, 2018, 35 (03) :E155-E158
[10]   Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Womens Health Initiative Observational Study [J].
Chlebowski, Rowan T. ;
Manson, JoAnn E. ;
Anderson, Garnet L. ;
Cauley, Jane A. ;
Aragaki, Aaron K. ;
Stefanick, Marcia L. ;
Lane, Dorothy S. ;
Johnson, Karen C. ;
Wactawski-Wende, Jean ;
Chen, Chu ;
Qi, Lihong ;
Yasmeen, Shagufta ;
Newcomb, Polly A. ;
Prentice, Ross L. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (08) :526-535